AI FOR SCIENCE · ON THE RECORD
Moderna
On the timeline →People filter →
Research on the record
- 2026-10-22Full Phase 3 data for Moderna and Merck's individualized melanoma vaccine: risk of recurrence or death cut 42% (HR 0.58), with no difference in the first six monthsLevel 5 · Used in practice
- 2026-09-16Moderna finds sampling protocol, not architecture, decided a GAN-vs-VAE antibody testLevel 4 · Tested in the physical world
- 2026-08-19An individualized cancer vaccine whose neoantigens an algorithm picks meets its Phase 3 endpointsLevel 5 · Used in practice
Graded by how far the evidence went, not how good the result is. See the methodology.
Read on AI4S.fyi
People
Only people the AI4S.fyi record has named: in a round, a timeline entry, commentary, an interview or a sourced role. Not the full team.
Named on AI4S.fyi
- AArkadij KummerAuthor affiliation on a 2026 paper Moderna finds sampling protocol, not architecture, decided a GAN-vs-VAE antibody test
- SSandeep KumarNow: Author affiliation on a 2026 paper · Moderna (Computational Science, Research and Early Development) Moderna finds sampling protocol, not architecture, decided a GAN-vs-VAE antibody test
This page compiles what AI4S.fyi has recorded and links each item to its source. It is not a grade of the organization and not its complete history: a blank means the record has not caught up as often as it means nothing happened.